Reformbiologics
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Series A | ||
* | N/A | $4.1m | Post IPO Equity |
Total Funding | - |
Related Content
Recent News about Reformbiologics
EditReForm Biologics operates in the biopharmaceutical industry, focusing on the formulation of biotherapeutics to enhance patient outcomes. The company has developed a proprietary technology platform that transforms the formulation of protein-based therapeutics. This platform extends product life cycles, enables alternative dosing methods, and improves manufacturing efficiency, thereby providing significant value to its biopharmaceutical partners. ReForm Biologics collaborates with drug companies through formulation development partnerships and product-specific licenses. The business model revolves around these collaborations and licensing agreements, which generate revenue by offering innovative solutions to improve the efficacy and delivery of biotherapeutics. The primary clients are biopharmaceutical companies looking to optimize their therapeutic products and manufacturing processes.
Keywords: biotherapeutics, technology platform, formulation development, protein therapeutics, product life cycles, alternative dosing, manufacturing efficiency, biopharmaceutical partners, licensing, patient outcomes.